Peijia Medical Ltd. ( (HK:9996) ) has shared an update.
Peijia Medical Ltd. announced a strong financial performance for the year ended December 31, 2024, with a 39.5% increase in revenue to RMB615.5 million. This growth was driven by high sales in both its Transcatheter Valve Therapeutic and Neurointerventional segments. The company expanded its market share in the Chinese transfemoral TAVR market, achieving a 25% share and surpassing 3,400 units in implantation volume. Additionally, the Neurointerventional Business achieved profitability, contributing RMB52.1 million in segment profit. The company’s operational losses narrowed significantly by 44.4%, reflecting improved operational performance and cost efficiency.
More about Peijia Medical Ltd.
Peijia Medical Ltd. operates in the medical device industry, focusing on products for valvular heart diseases and cerebrovascular diseases. The company is known for its Transcatheter Valve Therapeutic Business and Neurointerventional Business, with a significant presence in the Chinese market.
YTD Price Performance: 16.67%
Technical Sentiment Signal: Hold
Current Market Cap: €382.4M
For detailed information about 9996 stock, go to TipRanks’ Stock Analysis page.